Weight and breast cancer drugs: a missed connection?
NCT ID NCT02095184
First seen Apr 17, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This study looked at whether standard doses of hormone-lowering pills (aromatase inhibitors) work differently in overweight or obese postmenopausal women with breast cancer compared to normal-weight women. Researchers planned to measure changes in a tumor growth marker (Ki67) after 4 months of treatment. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.